Description: Helixmith Co., Ltd, a biotechnology company, discovers and develops biopharmaceuticals for human diseases. The company has a pipeline of novel biologics and herbal therapeutics in the areas of cardiovascular disease, cancer, and immune disorder, with clinical studies ongoing in the United States, Korea, and China. Its flagship product is VM202, a DNA-based drug for cardiovascular and neurological diseases. The company's pipeline products include VM206, a therapeutic cancer vaccine targeting HER2/neu positive breast or ovarian cancer; and VM501, a re-engineered form of interleukin 11 targeting chemotherapy-induced thrombocytopenia. Its clinical trials biologics comprise VM202-DPN, VM202-PAD, VM501, VM202-ALS, VM202-CAD, and VM206. The company was formerly known as ViroMed Co., Ltd. and changed its name to Helixmith Co., Ltd in April 2019. Helixmith Co., Ltd was incorporated in 1996 and is headquartered in Seoul, South Korea.
Home Page: www.helixmith.com
Building 203
Seoul,
151-747
South Korea
Phone:
82 2 2102 7200
Officers
| Name | Title |
|---|---|
| Mr. Sunyoung Kim D.Phil., Ph.D. | Founder, CEO & Director |
| Won Ho Park | Pres |
| Mr. Michael Na | CFO & Director of Office of Strategic Net Assessment |
| Mr. Seung-Shin Yu Ph.D. | CTO , Representative Director, MD of R&D Center and Intellectual Property & Director |
| Jun Tae Park Ph.D. | Exec. VP of Licensing & Regulatory Affairs |
| Miwon Son Ph.D. | Sr. Managing Director of Phytotherapeutics |
| William O. Frank | Head of Medical |
| Jong-Mook Kim Ph.D. | Director of Devel. Division & Strategic Bus. Division and Director |
Exchange: KQ
Country: KR
Currency: Korean Won (₩)
| GIC Sector: | Health Care |
|---|---|
| GIC Group: | Pharmaceuticals, Biotechnology & Life Sciences |
| GIC Industry: | Biotechnology |
| GIC Sub-Industry: | Biotechnology |
| Forward PE: | 0 |
|---|---|
| Trailing PE: | 0 |
| Price-to-Book MRQ: | 0 |
| Price-to-Sales TTM: | 87.9155 |
| IPO Date: | 2005-12-29 |
| Fiscal Year End: | December |
| Full Time Employees: | 106 |